|
TLA Buster
Tired of TLAs (Three letter acronyms)? Try seaching on
the acronym buster
|
| |
|
Ensuring Pharma and Biotech company valuations are maximised over the long-term
Tuesday 22nd November 2005, Four Seasons Hotel, London
Event timing
The event starts at 6.30pm (Registration from 6.00pm). The short talks and panel discussions last
approximately 1 ¼ hours and will be followed by cocktails and canapés - the ideal networking opportunity.
About the event
There is a lot of confusion in the market about whether to mark down 'big pharma' share prices,
whether to mark up any company involved in stem cell research or nanotechnology, or generally
how to value companies whose main asset is intellectual property. This networking evening will
look at how then Pharma and Biotech can best cut through the hubris and demonstrate real value for investors.
What (if anything) should the industry be doing differently - consolidating, becoming leaner,
concentrating on specific products, outsourcing more etc. in order to ensure that value is maximised?
Or conversely should management be focussed on long-term goals, not worrying too much if the company
is not valued as high as might otherwise have been the case?
In particular, the following issues will be addressed:
- How Pharma and Biotech valuations should reflect the fundamentals of product offerings and product development
- Is there an industry-specific business model for creating sustained growth and shareholder value?
- Are 'virtual companies' the best way forward to maximise value?
- The key corporate milestones for a Biotech company and how to achieve them
- Does the specialty pharmaceutical company model offer a better return to investors?
- The impact of drug policy on Pharma and Biotech investing and value
- Achieving a sustainable price for your company - is this more realistic than maximising the value?
- How much risk should be controlled in order to increase corporate value
- How investors value existing and potential IP
- Managing burn rates: generating revenue and controlling costs to preserve value
- How the investor spots which concepts could be products
- Ensuring you have an effective IR strategy/team
- The investors' perspective (if it's undervalued - invest, if it is not - do not invest).
Outstanding speaker panel
|
Andrew Fraser - Partner, 3i
Andrew is director of 3i's UK healthcare team, and has 10 years experience in venture capital investment in life sciences at 3i. Prior to 3i he worked at Price Waterhouse in London for six years. Andrew is currently responsible for a range of investments including Kudos Pharmaceuticals, Onyvax, ProStrakan, Oxagen, Inpharmatica, Arrow Therapeutics, Neurotech and Intercytex. Previous investments include LGC, Bradford Particle Design, Ribotargets and Pharmagene. Andrew serves on the board of Onyvax.
He graduated with a B.Com (Hons) degree in Business from Edinburgh University and qualified as a Chartered Accountant in 1991.
|
Dr Richard Palmer - Chief Executive Officer, Alizyme
Dr Palmer joined the Company in September 1996 and has been Chief Executive Officer of Alizyme since March 1997 and also retains overall responsibility for research and development. Previously at Wellcome and Glaxo Wellcome, he has 30 years' experience of research and development management.
|
|
|
Dr Geoffrey Guy - Executive Chairman, GW Pharmaceuticals
Dr Guy founded Ethical Holdings plc, in 1985 and led that company as Chairman and Chief Executive to its NASDAQ flotation in 1993 before leaving in 1997. He received 3i's "Venturer of the Year" award in the science and technology category. In 1990, Dr Guy co-founded the plant-medicines company that became Phytopharm plc, of which he was Chairman until 1997. Dr Guy served as Director of Clinical Development at Napp Laboratories from 1983 to 1985 and as International Clinical Research Co-ordinator at Laboratories Pierre Fabre from 1981 to 1983.
Dr Guy has over twenty years experience in pharmaceutical development covering new chemical entities, biotechnology products, plant-based medicines, controlled drugs and drug delivery systems. Dr Guy has been the physician in charge of over 200 clinical studies including first dose in man, pharmacokinetics, pharmacodynamics, dose-ranging, controlled clinical trials and large scale multi-centred studies and clinical surveys.
|
Dr Stephen Bunting - Managing Director, Abingworth Management Ltd
Stephen has a PhD in Biological Sciences and has been in the venture capital business since 1983, specialising in the biotechnology and medical field. Before joining Abingworth in 1987, he worked for N M Rothschild & Sons as an advisor to Biotechnology Investments Limited. His directorships have included Astex Technology, Aurora Biosciences, Cantab Pharmaceuticals, Devgen, Genetic Therapy, Hexagen and 3-Dimensional Pharmaceuticals.
|
|
Networking evening
One of the main reasons to attend this event is the opportunity to meet other key players within the industry,
whether they be CEOs, Finance Directors, other key Directors, Consultants, Lawyers etc. Due to the nature of
this event NSEP will be particularly targeting the investors, including venture capitalists, banks, fund
managers and corporate financial advisors.
The cocktail party immediately following the event (it is almost worth coming for the famous Four
Seasons canapés themselves!) is the ideal place to discuss matters in a less formal environment, whether
this discussion is directly related to the event topic or not.
Who will attend?Expected breakdown of job
titles
Expected breakdown by
audience sector
© NSEP 2007 -
All rights reserved
|